Evidence map›Paper›PMID 24317129›Full record

Trial reportBone marrow transplantation2014

Safety and efficacy of high-dose melphalan and auto-SCT in patients with AL amyloidosis and cardiac involvement.

S Girnius, D C Seldin, H K Meier-Ewert, J M Sloan, K Quillen, F L Ruberg, J L Berk, G Doros, V Sanchorawala

Abstract readClinical Trial
PubMed Publisher
In one paragraph

Trial report in Bone marrow transplantation, 2014. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 15 papers.

0numbers the graph read from it
0cells of the map it votes in
15citing papers in PubMed
2.2field-weighted citation impact, top 12% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

15 citing papers in PubMed, 45 citations in OpenAlex.

  1. Trial
  2. Trial
  3. Review
  4. Review
  5. Review
  6. Review
  7. Article
  8. Article
  9. Review
  10. Article
  11. Modified High-Dose Melphalan and Autologous Stem Cell Transplantation for Immunoglobulin Light Chain Amyloidosis.Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation · 2018
    Article
  12. Article
  13. Article
  14. Article
  15. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors at 2 institutions in 1 country.

S Girnius1] Department of Medicine, Amyloidosis Center, Boston University School of Medicine, Boston, MA, USA [2] Section of Hematology-Oncology, Department of Medicine, Boston Medical Center, Boston, MA, USA.
D C Seldin1] Department of Medicine, Amyloidosis Center, Boston University School of Medicine, Boston, MA, USA [2] Section of Hematology-Oncology, Department of Medicine, Boston Medical Center, Boston, MA, USA.
H K Meier-Ewert1] Department of Medicine, Amyloidosis Center, Boston University School of Medicine, Boston, MA, USA [2] Section of Cardiovascular Medicine, Department of Medicine, Boston Medical Center, Boston, MA, USA.
J M Sloan1] Department of Medicine, Amyloidosis Center, Boston University School of Medicine, Boston, MA, USA [2] Section of Hematology-Oncology, Department of Medicine, Boston Medical Center, Boston, MA, USA.
K Quillen1] Department of Medicine, Amyloidosis Center, Boston University School of Medicine, Boston, MA, USA [2] Section of Hematology-Oncology, Department of Medicine, Boston Medical Center, Boston, MA, USA [3] Department of Pathology and Laboratory Medicine, Boston Medical Center, Boston, MA, USA.
F L Ruberg1] Department of Medicine, Amyloidosis Center, Boston University School of Medicine, Boston, MA, USA [2] Section of Cardiovascular Medicine, Department of Medicine, Boston Medical Center, Boston, MA, USA.
J L Berk1] Department of Medicine, Amyloidosis Center, Boston University School of Medicine, Boston, MA, USA [2] Section of Pulmonary, Critical Care, and Allergy, Department of Medicine, Boston Medical Center, Boston, MA, USA.
G DorosDepartment of Biostatistics, Boston University School of Public Health, Boston, MA, USA.
V Sanchorawala1] Department of Medicine, Amyloidosis Center, Boston University School of Medicine, Boston, MA, USA [2] Section of Hematology-Oncology, Department of Medicine, Boston Medical Center, Boston, MA, USA.
Boston University · USAmyloidosis Foundation · US

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

In Ig light chain (AL) amyloidosis, cardiac involvement is associated with worse prognosis and increased treatment-related complications. In this retrospective cohort study, we assessed survival, hematologic and cardiac responses to high-dose melphalan and auto-SCT (HDM/SCT) in patients with AL amyloidosis and cardiac involvement, stratified by cardiac biomarkers brain natriuretic peptide and Troponin I, analogous to the Mayo cardiac staging. Forty-seven patients underwent HDM/SCT based upon functional measures; six patients had modified cardiac stage I disease, seventeen had modified cardiac stage II disease and twenty-four had modified cardiac stage III disease. Treatment-related mortality was 4% for all patients and 8% for patients with stage III disease. Three-year survival was 88% and EFS was 47%; these did not differ by stage. By intention-to-treat analysis, 27% of patients achieved a hematologic complete response and 32% a very good partial response, of whom 70 and 45%, respectively, have not required additional therapy at 36 months. Cardiac response was achieved in 53% of patients. We conclude that with appropriate patient selection and a risk-adapted treatment approach, HDM/SCT is safe and effective in patients with AL amyloidosis and cardiac involvement.

Indexed as

Stem Cell TransplantationAgedAmyloidosisBiomarkersFemaleFollow-Up StudiesHeart DiseasesHematopoietic Stem CellsHumansImmunoglobulin Light-chain AmyloidosisKaplan-Meier EstimateMaleMelphalanMiddle AgedNatriuretic Peptide, BrainPrognosisBiomarkersMelphalanNatriuretic Peptide, BrainTroponin I

Identifiers

PMID24317129
OpenAlexW2088466452

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.